Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

$24.99

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Long-term Activity Ratios (Summary)

Merck & Co. Inc., long-term (investment) activity ratios (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Net fixed asset turnover
Total asset turnover
Equity turnover

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The long-term activity ratios for the period between March 2022 and March 2026 exhibit a general trend of stability punctuated by specific periods of volatility, particularly regarding equity utilization and fixed asset efficiency.

Net Fixed Asset Turnover
The ratio reached a peak of 2.89 in September 2022 before initiating a gradual downward trajectory. A period of relative stabilization was observed between March 2024 and December 2024, with values ranging from 2.66 to 2.70. However, efficiency declined further during 2025, hitting a low of 2.51 in September 2025. The period concluded with a modest recovery to 2.59 by March 2026, suggesting a long-term decrease in the revenue-generating capacity of fixed assets.
Total Asset Turnover
This metric remained relatively consistent over the analyzed timeframe. After increasing from 0.51 in March 2022 to a peak of 0.58 in March 2024, the ratio experienced a contraction that bottomed out at 0.47 in September 2025. By March 2026, the ratio returned to 0.51, indicating that the overall efficiency of the asset base in producing sales remained stable despite transient fluctuations in late 2025.
Equity Turnover
Equity turnover demonstrated the highest degree of variance. After maintaining a level of 1.32 through much of 2022, the ratio rose significantly to peak at 1.60 in December 2023. This peak was followed by a sustained decline throughout 2024 and 2025, reaching a low of 1.24 in the final two quarters of 2025. A sharp rebound to 1.43 was recorded by March 2026, reflecting periodic shifts in the efficiency of shareholder equity in generating revenue.

The synchronized dip in all three turnover ratios during the third quarter of 2025, followed by a collective recovery in the first quarter of 2026, suggests a temporary systemic decline in operational efficiency or a significant increase in asset and equity bases that took several quarters to yield proportional revenue growth.


Net Fixed Asset Turnover

Merck & Co. Inc., net fixed asset turnover calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Sales
Property, plant and equipment, at cost, net of accumulated depreciation
Long-term Activity Ratio
Net fixed asset turnover1
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Net fixed asset turnover = (SalesQ1 2026 + SalesQ4 2025 + SalesQ3 2025 + SalesQ2 2025) ÷ Property, plant and equipment, at cost, net of accumulated depreciation
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of long-term investment activity indicates a period of consistent capital expenditure coupled with fluctuating revenue streams, resulting in a general decline in asset utilization efficiency over the observed period.

Revenue Trends
Sales exhibited a volatile but generally upward trajectory, starting at 15,901 million USD in March 2022 and reaching a peak of 17,276 million USD by September 2025. Despite this growth, quarterly fluctuations are evident, with notable troughs in December 2022 and December 2023, suggesting seasonal or cyclical variations in revenue generation.
Fixed Asset Investment
There is a consistent and steady increase in property, plant, and equipment, net of accumulated depreciation. The asset base grew from 19,747 million USD in March 2022 to 25,433 million USD by March 2026. This persistent upward trend reflects a sustained commitment to expanding physical infrastructure and production capacity.
Net Fixed Asset Turnover Performance
The net fixed asset turnover ratio demonstrates a gradual contraction over the long term. The ratio peaked at 2.89 in September 2022 but trended downward, reaching a low of 2.51 in September 2025. While there was a slight recovery to 2.59 by March 2026, the overall trend indicates that the growth in the fixed asset base has outpaced the growth in sales.
Efficiency Analysis
The divergence between the steady rise in net fixed assets and the more irregular growth in sales has led to a decrease in the efficiency with which the company generates revenue from its long-term investments. The decline in the turnover ratio suggests that recent capital expenditures have not yet yielded proportional increases in quarterly sales, indicating a period of asset integration or capacity underutilization.

Total Asset Turnover

Merck & Co. Inc., total asset turnover calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Sales
Total assets
Long-term Activity Ratio
Total asset turnover1
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Total asset turnover = (SalesQ1 2026 + SalesQ4 2025 + SalesQ3 2025 + SalesQ2 2025) ÷ Total assets
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The total asset turnover ratio demonstrates a period of moderate efficiency gains followed by a notable decline coinciding with significant asset expansion, before showing signs of stabilization in the final quarter of the analysis.

Efficiency Growth Phase (March 2022 – March 2024)
During this interval, a steady upward trend in asset utilization is observed. The total asset turnover ratio increased from 0.51 to a peak of 0.58. This improvement occurred while total assets remained relatively stable, fluctuating within a narrow range between 104 billion and 109 billion US dollars, suggesting that the increase in the ratio was driven by optimized operational efficiency and steady sales performance.
Asset Expansion and Turnover Compression (June 2024 – December 2025)
A marked shift in the ratio is evident starting in mid-2024. Total assets grew substantially, rising from approximately 112.6 billion US dollars in March 2024 to a peak of 136.9 billion US dollars by December 2025. While sales also reached a peak of 17.3 billion US dollars in September 2025, the growth in the asset base outpaced revenue generation. Consequently, the total asset turnover ratio experienced a significant contraction, reaching a period low of 0.47 by December 2025. This pattern indicates a period of heavy investment or acquisition where the new assets had not yet reached full revenue-generating capacity.
Recovery and Stabilization (March 2026)
In the final reported quarter, a recovery in efficiency is noted. The total asset turnover ratio rose back to 0.51. This improvement is attributed to a reduction in total assets to 128.7 billion US dollars while maintaining sales levels above 16 billion US dollars, suggesting a correction in the asset-to-sales relationship.

Overall, the long-term investment activity reflects a cycle of efficiency optimization followed by a strategic expansion of the balance sheet. The temporary dip in turnover suggests a lag between capital deployment and the realization of corresponding sales growth, a trend that began to reverse by the first quarter of 2026.


Equity Turnover

Merck & Co. Inc., equity turnover calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Sales
Total Merck & Co., Inc. stockholders’ equity
Long-term Activity Ratio
Equity turnover1
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Equity turnover = (SalesQ1 2026 + SalesQ4 2025 + SalesQ3 2025 + SalesQ2 2025) ÷ Total Merck & Co., Inc. stockholders’ equity
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


An analysis of the long-term investment activity indicates a fluctuating relationship between revenue generation and the company's equity base over the period from March 2022 to March 2026. While sales exhibited a general upward trajectory, the equity turnover ratio was primarily influenced by significant volatility in stockholders' equity.

Sales Performance Trends
Revenue demonstrated consistent growth over the analyzed period. Sales started at 15,901 million US$ in March 2022 and reached a peak of 17,276 million US$ in September 2025. Despite quarterly variations, there is a clear long-term increase in the top-line capacity, suggesting an expansion in market reach or pricing power.
Stockholders' Equity Volatility
The equity base experienced notable instability. A steady increase was observed throughout 2022, followed by a sharp contraction in 2023, where equity dropped to a low of 37,581 million US$ by December 31, 2023. This was followed by a recovery phase in 2024 and 2025, peaking at 52,606 million US$ in December 2025, before another significant reduction to 45,878 million US$ by March 2026.
Equity Turnover Ratio Dynamics
The equity turnover ratio fluctuated between a low of 1.24 and a high of 1.60. The peak ratio of 1.60 in December 2023 was not driven by record sales, but rather by the simultaneous contraction of stockholders' equity to its lowest point in the series. Conversely, the ratio declined to 1.24 during the latter half of 2025, as the equity base expanded to its maximum level, effectively diluting the asset turnover efficiency.
Correlation and Efficiency Insights
The data reveals that the efficiency of equity utilization is highly sensitive to changes in the capital structure. The jump in the turnover ratio to 1.43 in March 2026, following a period of decline, is attributable to the reduction in total equity rather than a surge in sales, which remained relatively flat between December 2025 and March 2026. This suggests that the observed increases in turnover are often the result of equity reductions rather than organic operational growth.